nodes	percent_of_prediction	percent_of_DWPC	metapath
Theophylline—CYP1B1—Doxorubicin—testicular cancer	0.0866	0.173	CbGbCtD
Theophylline—SLC22A7—Methotrexate—testicular cancer	0.0759	0.152	CbGbCtD
Theophylline—CYP2C8—Ifosfamide—testicular cancer	0.0673	0.135	CbGbCtD
Theophylline—CYP2C9—Ifosfamide—testicular cancer	0.0469	0.0938	CbGbCtD
Theophylline—CYP2E1—Etoposide—testicular cancer	0.0431	0.0861	CbGbCtD
Theophylline—CYP2C8—Etoposide—testicular cancer	0.0322	0.0643	CbGbCtD
Theophylline—CYP3A4—Ifosfamide—testicular cancer	0.0273	0.0546	CbGbCtD
Theophylline—CYP1A2—Etoposide—testicular cancer	0.0249	0.0498	CbGbCtD
Theophylline—CYP2C9—Cisplatin—testicular cancer	0.0228	0.0456	CbGbCtD
Theophylline—CYP2D6—Vinblastine—testicular cancer	0.0228	0.0455	CbGbCtD
Theophylline—CYP3A4—Vinblastine—testicular cancer	0.0145	0.0289	CbGbCtD
Theophylline—CYP2D6—Doxorubicin—testicular cancer	0.014	0.028	CbGbCtD
Theophylline—CYP3A4—Etoposide—testicular cancer	0.013	0.0261	CbGbCtD
Theophylline—CYP3A4—Doxorubicin—testicular cancer	0.0089	0.0178	CbGbCtD
Theophylline—ADA—Validated transcriptional targets of TAp63 isoforms—TFAP2C—testicular cancer	0.00844	0.0789	CbGpPWpGaD
Theophylline—HDAC2—Teniposide—Etoposide—testicular cancer	0.00451	1	CbGdCrCtD
Theophylline—HDAC2—embryo—testicular cancer	0.00338	0.0477	CbGeAlD
Theophylline—PDE4C—G alpha (s) signalling events—INSL3—testicular cancer	0.00315	0.0295	CbGpPWpGaD
Theophylline—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00302	0.0282	CbGpPWpGaD
Theophylline—PDE3B—PKB-mediated events—STK11—testicular cancer	0.00292	0.0273	CbGpPWpGaD
Theophylline—ADORA2B—G alpha (s) signalling events—INSL3—testicular cancer	0.00288	0.0269	CbGpPWpGaD
Theophylline—PDE3B—testis—testicular cancer	0.00281	0.0397	CbGeAlD
Theophylline—PDE3B—G alpha (s) signalling events—INSL3—testicular cancer	0.00279	0.0261	CbGpPWpGaD
Theophylline—PDE4D—G alpha (s) signalling events—INSL3—testicular cancer	0.00275	0.0257	CbGpPWpGaD
Theophylline—ADORA2A—gonad—testicular cancer	0.00269	0.038	CbGeAlD
Theophylline—PDE4D—female gonad—testicular cancer	0.00265	0.0374	CbGeAlD
Theophylline—PDE4A—G alpha (s) signalling events—INSL3—testicular cancer	0.00261	0.0244	CbGpPWpGaD
Theophylline—PDE3A—G alpha (s) signalling events—INSL3—testicular cancer	0.00254	0.0238	CbGpPWpGaD
Theophylline—PDE5A—gonad—testicular cancer	0.00245	0.0346	CbGeAlD
Theophylline—PDE4B—G alpha (s) signalling events—INSL3—testicular cancer	0.00242	0.0226	CbGpPWpGaD
Theophylline—PDE4D—testis—testicular cancer	0.00235	0.0332	CbGeAlD
Theophylline—PDE4A—female gonad—testicular cancer	0.00234	0.0331	CbGeAlD
Theophylline—ADORA2B—testis—testicular cancer	0.00233	0.0329	CbGeAlD
Theophylline—HDAC2—gonad—testicular cancer	0.0023	0.0324	CbGeAlD
Theophylline—ADA—testis—testicular cancer	0.00213	0.0301	CbGeAlD
Theophylline—PDE4A—testis—testicular cancer	0.00208	0.0293	CbGeAlD
Theophylline—ADA—C-MYB transcription factor network—MAD1L1—testicular cancer	0.00206	0.0193	CbGpPWpGaD
Theophylline—PDE3B—lymph node—testicular cancer	0.00204	0.0288	CbGeAlD
Theophylline—PDE5A—female gonad—testicular cancer	0.00199	0.0281	CbGeAlD
Theophylline—ADORA2A—testis—testicular cancer	0.00194	0.0274	CbGeAlD
Theophylline—PDE3A—female gonad—testicular cancer	0.00194	0.0274	CbGeAlD
Theophylline—SLC22A7—testis—testicular cancer	0.00192	0.0271	CbGeAlD
Theophylline—ADORA2A—G alpha (s) signalling events—INSL3—testicular cancer	0.00189	0.0177	CbGpPWpGaD
Theophylline—HDAC2—Epigenetic regulation of gene expression—DNMT3L—testicular cancer	0.00188	0.0176	CbGpPWpGaD
Theophylline—HDAC2—female gonad—testicular cancer	0.00187	0.0263	CbGeAlD
Theophylline—ADORA2B—C-MYB transcription factor network—MAD1L1—testicular cancer	0.0018	0.0169	CbGpPWpGaD
Theophylline—PDE5A—testis—testicular cancer	0.00177	0.0249	CbGeAlD
Theophylline—PDE4B—gonad—testicular cancer	0.00172	0.0243	CbGeAlD
Theophylline—PDE3A—testis—testicular cancer	0.00172	0.0243	CbGeAlD
Theophylline—PDE4D—lymph node—testicular cancer	0.0017	0.024	CbGeAlD
Theophylline—ADORA1—testis—testicular cancer	0.00168	0.0236	CbGeAlD
Theophylline—HDAC2—testis—testicular cancer	0.00166	0.0234	CbGeAlD
Theophylline—ADA—lymph node—testicular cancer	0.00155	0.0218	CbGeAlD
Theophylline—PDE4A—lymph node—testicular cancer	0.00151	0.0213	CbGeAlD
Theophylline—CYP1B1—gonad—testicular cancer	0.00147	0.0208	CbGeAlD
Theophylline—ADA—C-MYB transcription factor network—H2AFZ—testicular cancer	0.00144	0.0134	CbGpPWpGaD
Theophylline—PDE3B—PI3K Cascade—STK11—testicular cancer	0.00144	0.0134	CbGpPWpGaD
Theophylline—PDE4B—female gonad—testicular cancer	0.0014	0.0197	CbGeAlD
Theophylline—SLC22A7—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00137	0.0128	CbGpPWpGaD
Theophylline—ADORA2B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00137	0.0128	CbGpPWpGaD
Theophylline—ADA—C-MYB transcription factor network—KITLG—testicular cancer	0.00132	0.0124	CbGpPWpGaD
Theophylline—CYP2E1—seminal vesicle—testicular cancer	0.00131	0.0186	CbGeAlD
Theophylline—CYP1B1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.00129	0.0121	CbGpPWpGaD
Theophylline—PDE5A—lymph node—testicular cancer	0.00128	0.0181	CbGeAlD
Theophylline—ADORA2B—C-MYB transcription factor network—H2AFZ—testicular cancer	0.00126	0.0118	CbGpPWpGaD
Theophylline—PDE3A—lymph node—testicular cancer	0.00125	0.0176	CbGeAlD
Theophylline—PDE4B—testis—testicular cancer	0.00124	0.0175	CbGeAlD
Theophylline—ADORA1—lymph node—testicular cancer	0.00121	0.0171	CbGeAlD
Theophylline—CYP1B1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.00121	0.0113	CbGpPWpGaD
Theophylline—PDE3B—IRS-mediated signalling—STK11—testicular cancer	0.0012	0.0112	CbGpPWpGaD
Theophylline—HDAC2—lymph node—testicular cancer	0.0012	0.0169	CbGeAlD
Theophylline—CYP1B1—female gonad—testicular cancer	0.0012	0.0169	CbGeAlD
Theophylline—PDE3B—IRS-related events—STK11—testicular cancer	0.00117	0.0109	CbGpPWpGaD
Theophylline—ADORA1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00117	0.0109	CbGpPWpGaD
Theophylline—PDE3B—IRS-related events triggered by IGF1R—STK11—testicular cancer	0.00116	0.0108	CbGpPWpGaD
Theophylline—ADORA2B—C-MYB transcription factor network—KITLG—testicular cancer	0.00116	0.0108	CbGpPWpGaD
Theophylline—PDE3B—Insulin receptor signalling cascade—STK11—testicular cancer	0.00113	0.0105	CbGpPWpGaD
Theophylline—PDE3B—IGF1R signaling cascade—STK11—testicular cancer	0.00113	0.0105	CbGpPWpGaD
Theophylline—HDAC2—Cell Cycle—MAD1L1—testicular cancer	0.00109	0.0102	CbGpPWpGaD
Theophylline—CYP1B1—testis—testicular cancer	0.00106	0.015	CbGeAlD
Theophylline—ADORA2B—GPCR ligand binding—INSL3—testicular cancer	0.00104	0.00976	CbGpPWpGaD
Theophylline—Alopecia—Vinblastine—testicular cancer	0.000996	0.00314	CcSEcCtD
Theophylline—PDE3B—PI3K Cascade—FGFR3—testicular cancer	0.000988	0.00923	CbGpPWpGaD
Theophylline—Agitation—Chlorambucil—testicular cancer	0.000984	0.0031	CcSEcCtD
Theophylline—Ventricular arrhythmia—Epirubicin—testicular cancer	0.000969	0.00305	CcSEcCtD
Theophylline—Irritability—Cisplatin—testicular cancer	0.000967	0.00305	CcSEcCtD
Theophylline—Albuminuria—Epirubicin—testicular cancer	0.00096	0.00303	CcSEcCtD
Theophylline—Anaphylactoid reaction—Etoposide—testicular cancer	0.000959	0.00302	CcSEcCtD
Theophylline—Haematemesis—Doxorubicin—testicular cancer	0.000955	0.00301	CcSEcCtD
Theophylline—Hypercalcaemia—Doxorubicin—testicular cancer	0.000955	0.00301	CcSEcCtD
Theophylline—PDE3B—Signaling by Insulin receptor—STK11—testicular cancer	0.000937	0.00876	CbGpPWpGaD
Theophylline—Convulsion—Chlorambucil—testicular cancer	0.000927	0.00292	CcSEcCtD
Theophylline—Hypokalaemia—Cisplatin—testicular cancer	0.000922	0.00291	CcSEcCtD
Theophylline—Hyperglycaemia—Ifosfamide—testicular cancer	0.000917	0.00289	CcSEcCtD
Theophylline—ADA—C-MYB transcription factor network—KIT—testicular cancer	0.000903	0.00843	CbGpPWpGaD
Theophylline—ADORA2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000901	0.00842	CbGpPWpGaD
Theophylline—PDE4B—lymph node—testicular cancer	0.000898	0.0127	CbGeAlD
Theophylline—Ventricular arrhythmia—Doxorubicin—testicular cancer	0.000896	0.00282	CcSEcCtD
Theophylline—Albuminuria—Doxorubicin—testicular cancer	0.000889	0.0028	CcSEcCtD
Theophylline—ADORA1—GPCR ligand binding—INSL3—testicular cancer	0.000889	0.0083	CbGpPWpGaD
Theophylline—Flushing—Bleomycin—testicular cancer	0.000883	0.00278	CcSEcCtD
Theophylline—Extravasation—Methotrexate—testicular cancer	0.000878	0.00277	CcSEcCtD
Theophylline—Infection—Chlorambucil—testicular cancer	0.000868	0.00273	CcSEcCtD
Theophylline—Haematuria—Ifosfamide—testicular cancer	0.000864	0.00272	CcSEcCtD
Theophylline—Convulsion—Vinblastine—testicular cancer	0.00085	0.00268	CcSEcCtD
Theophylline—CYP1A1—female gonad—testicular cancer	0.000847	0.0119	CbGeAlD
Theophylline—Alopecia—Bleomycin—testicular cancer	0.000841	0.00265	CcSEcCtD
Theophylline—Anorexia—Chlorambucil—testicular cancer	0.000833	0.00262	CcSEcCtD
Theophylline—PDE3B—IRS-mediated signalling—FGFR3—testicular cancer	0.000826	0.00772	CbGpPWpGaD
Theophylline—Hyperuricaemia—Methotrexate—testicular cancer	0.000826	0.0026	CcSEcCtD
Theophylline—Flushing—Dactinomycin—testicular cancer	0.000824	0.0026	CcSEcCtD
Theophylline—Extravasation—Epirubicin—testicular cancer	0.000822	0.00259	CcSEcCtD
Theophylline—CYP2C8—testis—testicular cancer	0.000814	0.0115	CbGeAlD
Theophylline—PDE3B—IRS-related events—FGFR3—testicular cancer	0.000804	0.00751	CbGpPWpGaD
Theophylline—PDE3B—IRS-related events triggered by IGF1R—FGFR3—testicular cancer	0.000797	0.00744	CbGpPWpGaD
Theophylline—CYP1A1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000796	0.00744	CbGpPWpGaD
Theophylline—Ventricular extrasystoles—Epirubicin—testicular cancer	0.000794	0.0025	CcSEcCtD
Theophylline—ADORA2B—C-MYB transcription factor network—KIT—testicular cancer	0.00079	0.00738	CbGpPWpGaD
Theophylline—Alopecia—Dactinomycin—testicular cancer	0.000784	0.00247	CcSEcCtD
Theophylline—Blood uric acid increased—Methotrexate—testicular cancer	0.00078	0.00246	CcSEcCtD
Theophylline—PDE3B—Insulin receptor signalling cascade—FGFR3—testicular cancer	0.000776	0.00725	CbGpPWpGaD
Theophylline—PDE3B—IGF1R signaling cascade—FGFR3—testicular cancer	0.000776	0.00725	CbGpPWpGaD
Theophylline—Hyperuricaemia—Epirubicin—testicular cancer	0.000773	0.00244	CcSEcCtD
Theophylline—CYP1B1—lymph node—testicular cancer	0.00077	0.0109	CbGeAlD
Theophylline—Anorexia—Vinblastine—testicular cancer	0.000763	0.0024	CcSEcCtD
Theophylline—HDAC2—NoRC negatively regulates rRNA expression—H2AFZ—testicular cancer	0.000761	0.00711	CbGpPWpGaD
Theophylline—Extravasation—Doxorubicin—testicular cancer	0.00076	0.0024	CcSEcCtD
Theophylline—Decreased appetite—Chlorambucil—testicular cancer	0.000759	0.00239	CcSEcCtD
Theophylline—Flushing—Ifosfamide—testicular cancer	0.000755	0.00238	CcSEcCtD
Theophylline—CYP1A1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000745	0.00696	CbGpPWpGaD
Theophylline—HDAC2—Negative epigenetic regulation of rRNA expression—H2AFZ—testicular cancer	0.000743	0.00694	CbGpPWpGaD
Theophylline—HDAC2—RNA Polymerase I Promoter Clearance—H2AFZ—testicular cancer	0.000743	0.00694	CbGpPWpGaD
Theophylline—Ventricular extrasystoles—Doxorubicin—testicular cancer	0.000734	0.00231	CcSEcCtD
Theophylline—HDAC2—RNA Polymerase I Transcription—H2AFZ—testicular cancer	0.000732	0.00684	CbGpPWpGaD
Theophylline—Blood uric acid increased—Epirubicin—testicular cancer	0.00073	0.0023	CcSEcCtD
Theophylline—Arrhythmia—Ifosfamide—testicular cancer	0.000727	0.00229	CcSEcCtD
Theophylline—Alopecia—Ifosfamide—testicular cancer	0.000719	0.00226	CcSEcCtD
Theophylline—Hyperuricaemia—Doxorubicin—testicular cancer	0.000715	0.00225	CcSEcCtD
Theophylline—Gastrointestinal pain—Chlorambucil—testicular cancer	0.000714	0.00225	CcSEcCtD
Theophylline—Dermatitis contact—Epirubicin—testicular cancer	0.000709	0.00223	CcSEcCtD
Theophylline—Coma—Methotrexate—testicular cancer	0.0007	0.00221	CcSEcCtD
Theophylline—HDAC2—Cell Cycle—KITLG—testicular cancer	0.0007	0.00654	CbGpPWpGaD
Theophylline—SLC22A7—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000697	0.00652	CbGpPWpGaD
Theophylline—Decreased appetite—Vinblastine—testicular cancer	0.000696	0.00219	CcSEcCtD
Theophylline—Urticaria—Chlorambucil—testicular cancer	0.000694	0.00219	CcSEcCtD
Theophylline—Abdominal pain—Chlorambucil—testicular cancer	0.000691	0.00218	CcSEcCtD
Theophylline—Body temperature increased—Chlorambucil—testicular cancer	0.000691	0.00218	CcSEcCtD
Theophylline—ADORA2A—GPCR ligand binding—INSL3—testicular cancer	0.000686	0.00641	CbGpPWpGaD
Theophylline—CYP2E1—testis—testicular cancer	0.000685	0.00966	CbGeAlD
Theophylline—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000683	0.00638	CbGpPWpGaD
Theophylline—Anaphylactic shock—Bleomycin—testicular cancer	0.000676	0.00213	CcSEcCtD
Theophylline—Blood uric acid increased—Doxorubicin—testicular cancer	0.000676	0.00213	CcSEcCtD
Theophylline—Infection—Bleomycin—testicular cancer	0.000672	0.00212	CcSEcCtD
Theophylline—HDAC2—Epigenetic regulation of gene expression—H2AFZ—testicular cancer	0.000659	0.00616	CbGpPWpGaD
Theophylline—Dermatitis contact—Doxorubicin—testicular cancer	0.000656	0.00207	CcSEcCtD
Theophylline—Coma—Epirubicin—testicular cancer	0.000655	0.00206	CcSEcCtD
Theophylline—Gastrointestinal pain—Vinblastine—testicular cancer	0.000655	0.00206	CcSEcCtD
Theophylline—Flushing—Cisplatin—testicular cancer	0.000651	0.00205	CcSEcCtD
Theophylline—Agitation—Ifosfamide—testicular cancer	0.000651	0.00205	CcSEcCtD
Theophylline—PDE4C—GPCR downstream signaling—INSL3—testicular cancer	0.000647	0.00605	CbGpPWpGaD
Theophylline—Anorexia—Bleomycin—testicular cancer	0.000644	0.00203	CcSEcCtD
Theophylline—PDE3B—Signaling by Insulin receptor—FGFR3—testicular cancer	0.000644	0.00602	CbGpPWpGaD
Theophylline—Hypersensitivity—Chlorambucil—testicular cancer	0.000644	0.00203	CcSEcCtD
Theophylline—Polyuria—Methotrexate—testicular cancer	0.000633	0.002	CcSEcCtD
Theophylline—Abdominal pain—Vinblastine—testicular cancer	0.000633	0.00199	CcSEcCtD
Theophylline—Hypotension—Bleomycin—testicular cancer	0.000632	0.00199	CcSEcCtD
Theophylline—Infection—Dactinomycin—testicular cancer	0.000626	0.00197	CcSEcCtD
Theophylline—Arrhythmia—Cisplatin—testicular cancer	0.000626	0.00197	CcSEcCtD
Theophylline—Palpitations—Ifosfamide—testicular cancer	0.000626	0.00197	CcSEcCtD
Theophylline—Alopecia—Cisplatin—testicular cancer	0.00062	0.00195	CcSEcCtD
Theophylline—Pruritus—Chlorambucil—testicular cancer	0.000618	0.00195	CcSEcCtD
Theophylline—Convulsion—Ifosfamide—testicular cancer	0.000613	0.00193	CcSEcCtD
Theophylline—CYP2D6—female gonad—testicular cancer	0.000611	0.00863	CbGeAlD
Theophylline—Coma—Doxorubicin—testicular cancer	0.000606	0.00191	CcSEcCtD
Theophylline—Phlebitis—Epirubicin—testicular cancer	0.000604	0.0019	CcSEcCtD
Theophylline—Anorexia—Dactinomycin—testicular cancer	0.000601	0.00189	CcSEcCtD
Theophylline—Diarrhoea—Chlorambucil—testicular cancer	0.000598	0.00188	CcSEcCtD
Theophylline—Flushing—Etoposide—testicular cancer	0.000596	0.00188	CcSEcCtD
Theophylline—ADORA2B—GPCR downstream signaling—INSL3—testicular cancer	0.000591	0.00552	CbGpPWpGaD
Theophylline—Hypersensitivity—Vinblastine—testicular cancer	0.00059	0.00186	CcSEcCtD
Theophylline—Dermatitis exfoliative—Methotrexate—testicular cancer	0.000589	0.00186	CcSEcCtD
Theophylline—Decreased appetite—Bleomycin—testicular cancer	0.000588	0.00185	CcSEcCtD
Theophylline—PDE4C—Signaling by GPCR—INSL3—testicular cancer	0.000588	0.00549	CbGpPWpGaD
Theophylline—HDAC2—RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription—H2AFZ—testicular cancer	0.000584	0.00545	CbGpPWpGaD
Theophylline—Anaphylactic shock—Ifosfamide—testicular cancer	0.000578	0.00182	CcSEcCtD
Theophylline—Anaphylactoid reaction—Methotrexate—testicular cancer	0.000575	0.00181	CcSEcCtD
Theophylline—Infection—Ifosfamide—testicular cancer	0.000574	0.00181	CcSEcCtD
Theophylline—PDE3B—GPCR downstream signaling—INSL3—testicular cancer	0.000573	0.00535	CbGpPWpGaD
Theophylline—Tremor—Cisplatin—testicular cancer	0.000572	0.0018	CcSEcCtD
Theophylline—Alopecia—Etoposide—testicular cancer	0.000568	0.00179	CcSEcCtD
Theophylline—Nervous system disorder—Ifosfamide—testicular cancer	0.000567	0.00179	CcSEcCtD
Theophylline—PDE4D—GPCR downstream signaling—INSL3—testicular cancer	0.000563	0.00526	CbGpPWpGaD
Theophylline—Phlebitis—Doxorubicin—testicular cancer	0.000559	0.00176	CcSEcCtD
Theophylline—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000556	0.00519	CbGpPWpGaD
Theophylline—Vomiting—Chlorambucil—testicular cancer	0.000555	0.00175	CcSEcCtD
Theophylline—Dermatitis exfoliative—Epirubicin—testicular cancer	0.000552	0.00174	CcSEcCtD
Theophylline—Anorexia—Ifosfamide—testicular cancer	0.000551	0.00174	CcSEcCtD
Theophylline—Decreased appetite—Dactinomycin—testicular cancer	0.000548	0.00173	CcSEcCtD
Theophylline—Diarrhoea—Vinblastine—testicular cancer	0.000548	0.00173	CcSEcCtD
Theophylline—CYP1A1—lymph node—testicular cancer	0.000544	0.00768	CbGeAlD
Theophylline—CYP2D6—testis—testicular cancer	0.000542	0.00765	CbGeAlD
Theophylline—Hypotension—Ifosfamide—testicular cancer	0.00054	0.0017	CcSEcCtD
Theophylline—Anaphylactoid reaction—Epirubicin—testicular cancer	0.000538	0.00169	CcSEcCtD
Theophylline—Urticaria—Bleomycin—testicular cancer	0.000537	0.00169	CcSEcCtD
Theophylline—ADORA2B—Signaling by GPCR—INSL3—testicular cancer	0.000536	0.00501	CbGpPWpGaD
Theophylline—PDE4A—GPCR downstream signaling—INSL3—testicular cancer	0.000536	0.00501	CbGpPWpGaD
Theophylline—Body temperature increased—Bleomycin—testicular cancer	0.000534	0.00168	CcSEcCtD
Theophylline—Irritability—Methotrexate—testicular cancer	0.000531	0.00167	CcSEcCtD
Theophylline—Dizziness—Vinblastine—testicular cancer	0.000529	0.00167	CcSEcCtD
Theophylline—Convulsion—Cisplatin—testicular cancer	0.000529	0.00167	CcSEcCtD
Theophylline—HDAC2—Neural Crest Differentiation—FGFR3—testicular cancer	0.000524	0.0049	CbGpPWpGaD
Theophylline—PDE3A—GPCR downstream signaling—INSL3—testicular cancer	0.000522	0.00487	CbGpPWpGaD
Theophylline—PDE3B—Signaling by GPCR—INSL3—testicular cancer	0.00052	0.00486	CbGpPWpGaD
Theophylline—Nausea—Chlorambucil—testicular cancer	0.000519	0.00163	CcSEcCtD
Theophylline—Anxiety—Cisplatin—testicular cancer	0.000518	0.00163	CcSEcCtD
Theophylline—Gastrointestinal pain—Dactinomycin—testicular cancer	0.000516	0.00162	CcSEcCtD
Theophylline—HDAC2—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—testicular cancer	0.000514	0.0048	CbGpPWpGaD
Theophylline—PDE4D—Signaling by GPCR—INSL3—testicular cancer	0.000512	0.00478	CbGpPWpGaD
Theophylline—Dermatitis exfoliative—Doxorubicin—testicular cancer	0.00051	0.00161	CcSEcCtD
Theophylline—Vomiting—Vinblastine—testicular cancer	0.000509	0.0016	CcSEcCtD
Theophylline—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000508	0.00474	CbGpPWpGaD
Theophylline—Decreased appetite—Ifosfamide—testicular cancer	0.000502	0.00158	CcSEcCtD
Theophylline—ADORA1—GPCR downstream signaling—INSL3—testicular cancer	0.000502	0.00469	CbGpPWpGaD
Theophylline—Headache—Vinblastine—testicular cancer	0.000501	0.00158	CcSEcCtD
Theophylline—Abdominal pain—Dactinomycin—testicular cancer	0.000498	0.00157	CcSEcCtD
Theophylline—Body temperature increased—Dactinomycin—testicular cancer	0.000498	0.00157	CcSEcCtD
Theophylline—Anaphylactic shock—Cisplatin—testicular cancer	0.000498	0.00157	CcSEcCtD
Theophylline—Hypersensitivity—Bleomycin—testicular cancer	0.000498	0.00157	CcSEcCtD
Theophylline—Anaphylactoid reaction—Doxorubicin—testicular cancer	0.000498	0.00157	CcSEcCtD
Theophylline—PDE4B—GPCR downstream signaling—INSL3—testicular cancer	0.000496	0.00464	CbGpPWpGaD
Theophylline—Infection—Cisplatin—testicular cancer	0.000495	0.00156	CcSEcCtD
Theophylline—Nervous system disorder—Cisplatin—testicular cancer	0.000489	0.00154	CcSEcCtD
Theophylline—PDE4A—Signaling by GPCR—INSL3—testicular cancer	0.000487	0.00455	CbGpPWpGaD
Theophylline—Tachycardia—Cisplatin—testicular cancer	0.000486	0.00153	CcSEcCtD
Theophylline—Convulsion—Etoposide—testicular cancer	0.000484	0.00153	CcSEcCtD
Theophylline—Pruritus—Bleomycin—testicular cancer	0.000478	0.00151	CcSEcCtD
Theophylline—Nausea—Vinblastine—testicular cancer	0.000475	0.0015	CcSEcCtD
Theophylline—Abdominal pain upper—Epirubicin—testicular cancer	0.000475	0.0015	CcSEcCtD
Theophylline—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000475	0.00444	CbGpPWpGaD
Theophylline—Anorexia—Cisplatin—testicular cancer	0.000475	0.0015	CcSEcCtD
Theophylline—PDE3A—Signaling by GPCR—INSL3—testicular cancer	0.000474	0.00443	CbGpPWpGaD
Theophylline—Hypokalaemia—Epirubicin—testicular cancer	0.000474	0.00149	CcSEcCtD
Theophylline—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000472	0.00149	CcSEcCtD
Theophylline—Hypotension—Cisplatin—testicular cancer	0.000465	0.00147	CcSEcCtD
Theophylline—Hypersensitivity—Dactinomycin—testicular cancer	0.000465	0.00146	CcSEcCtD
Theophylline—Urticaria—Ifosfamide—testicular cancer	0.000459	0.00145	CcSEcCtD
Theophylline—Abdominal pain—Ifosfamide—testicular cancer	0.000457	0.00144	CcSEcCtD
Theophylline—Body temperature increased—Ifosfamide—testicular cancer	0.000457	0.00144	CcSEcCtD
Theophylline—Anaphylactic shock—Etoposide—testicular cancer	0.000456	0.00144	CcSEcCtD
Theophylline—ADORA1—Signaling by GPCR—INSL3—testicular cancer	0.000456	0.00426	CbGpPWpGaD
Theophylline—Infection—Etoposide—testicular cancer	0.000453	0.00143	CcSEcCtD
Theophylline—PDE4B—Signaling by GPCR—INSL3—testicular cancer	0.000451	0.00421	CbGpPWpGaD
Theophylline—CYP1B1—Biological oxidations—HPGDS—testicular cancer	0.00045	0.00421	CbGpPWpGaD
Theophylline—Tachycardia—Etoposide—testicular cancer	0.000445	0.0014	CcSEcCtD
Theophylline—Abdominal pain upper—Doxorubicin—testicular cancer	0.00044	0.00139	CcSEcCtD
Theophylline—Hypokalaemia—Doxorubicin—testicular cancer	0.000438	0.00138	CcSEcCtD
Theophylline—Anorexia—Etoposide—testicular cancer	0.000435	0.00137	CcSEcCtD
Theophylline—Decreased appetite—Cisplatin—testicular cancer	0.000433	0.00136	CcSEcCtD
Theophylline—Diarrhoea—Dactinomycin—testicular cancer	0.000431	0.00136	CcSEcCtD
Theophylline—Vomiting—Bleomycin—testicular cancer	0.00043	0.00135	CcSEcCtD
Theophylline—Hypotension—Etoposide—testicular cancer	0.000426	0.00134	CcSEcCtD
Theophylline—Rash—Bleomycin—testicular cancer	0.000426	0.00134	CcSEcCtD
Theophylline—Dermatitis—Bleomycin—testicular cancer	0.000426	0.00134	CcSEcCtD
Theophylline—Hypersensitivity—Ifosfamide—testicular cancer	0.000426	0.00134	CcSEcCtD
Theophylline—HDAC2—Chromatin modifying enzymes—H2AFZ—testicular cancer	0.000416	0.00388	CbGpPWpGaD
Theophylline—Pruritus—Ifosfamide—testicular cancer	0.000409	0.00129	CcSEcCtD
Theophylline—Haematuria—Methotrexate—testicular cancer	0.000409	0.00129	CcSEcCtD
Theophylline—Hyperglycaemia—Epirubicin—testicular cancer	0.000406	0.00128	CcSEcCtD
Theophylline—Nausea—Bleomycin—testicular cancer	0.000402	0.00127	CcSEcCtD
Theophylline—Vomiting—Dactinomycin—testicular cancer	0.000401	0.00126	CcSEcCtD
Theophylline—Rash—Dactinomycin—testicular cancer	0.000398	0.00125	CcSEcCtD
Theophylline—Decreased appetite—Etoposide—testicular cancer	0.000397	0.00125	CcSEcCtD
Theophylline—HDAC2—Transcription—H2AFZ—testicular cancer	0.000396	0.0037	CbGpPWpGaD
Theophylline—Diarrhoea—Ifosfamide—testicular cancer	0.000395	0.00125	CcSEcCtD
Theophylline—Body temperature increased—Cisplatin—testicular cancer	0.000394	0.00124	CcSEcCtD
Theophylline—ADORA2A—GPCR downstream signaling—INSL3—testicular cancer	0.000388	0.00362	CbGpPWpGaD
Theophylline—Haematuria—Epirubicin—testicular cancer	0.000382	0.0012	CcSEcCtD
Theophylline—Dizziness—Ifosfamide—testicular cancer	0.000382	0.0012	CcSEcCtD
Theophylline—Hyperglycaemia—Doxorubicin—testicular cancer	0.000375	0.00118	CcSEcCtD
Theophylline—Nausea—Dactinomycin—testicular cancer	0.000375	0.00118	CcSEcCtD
Theophylline—Gastrointestinal pain—Etoposide—testicular cancer	0.000373	0.00118	CcSEcCtD
Theophylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000371	0.00346	CbGpPWpGaD
Theophylline—Vomiting—Ifosfamide—testicular cancer	0.000367	0.00116	CcSEcCtD
Theophylline—Hypersensitivity—Cisplatin—testicular cancer	0.000367	0.00116	CcSEcCtD
Theophylline—Rash—Ifosfamide—testicular cancer	0.000364	0.00115	CcSEcCtD
Theophylline—Dermatitis—Ifosfamide—testicular cancer	0.000364	0.00115	CcSEcCtD
Theophylline—Urticaria—Etoposide—testicular cancer	0.000363	0.00114	CcSEcCtD
Theophylline—Abdominal pain—Etoposide—testicular cancer	0.000361	0.00114	CcSEcCtD
Theophylline—Body temperature increased—Etoposide—testicular cancer	0.000361	0.00114	CcSEcCtD
Theophylline—Haematuria—Doxorubicin—testicular cancer	0.000354	0.00111	CcSEcCtD
Theophylline—ADORA2A—Signaling by GPCR—INSL3—testicular cancer	0.000352	0.00329	CbGpPWpGaD
Theophylline—PDE4C—Signaling Pathways—INSL3—testicular cancer	0.000347	0.00324	CbGpPWpGaD
Theophylline—Nausea—Ifosfamide—testicular cancer	0.000343	0.00108	CcSEcCtD
Theophylline—Diarrhoea—Cisplatin—testicular cancer	0.000341	0.00107	CcSEcCtD
Theophylline—Alopecia—Methotrexate—testicular cancer	0.00034	0.00107	CcSEcCtD
Theophylline—Hypersensitivity—Etoposide—testicular cancer	0.000336	0.00106	CcSEcCtD
Theophylline—Flushing—Epirubicin—testicular cancer	0.000334	0.00105	CcSEcCtD
Theophylline—HDAC2—Direct p53 effectors—MMP2—testicular cancer	0.000328	0.00307	CbGpPWpGaD
Theophylline—Pruritus—Etoposide—testicular cancer	0.000323	0.00102	CcSEcCtD
Theophylline—Arrhythmia—Epirubicin—testicular cancer	0.000322	0.00101	CcSEcCtD
Theophylline—Alopecia—Epirubicin—testicular cancer	0.000318	0.001	CcSEcCtD
Theophylline—ADORA2B—Signaling Pathways—INSL3—testicular cancer	0.000317	0.00296	CbGpPWpGaD
Theophylline—Vomiting—Cisplatin—testicular cancer	0.000317	0.000998	CcSEcCtD
Theophylline—HDAC2—Gene Expression—DNMT3L—testicular cancer	0.000315	0.00294	CbGpPWpGaD
Theophylline—Rash—Cisplatin—testicular cancer	0.000314	0.00099	CcSEcCtD
Theophylline—Dermatitis—Cisplatin—testicular cancer	0.000314	0.000989	CcSEcCtD
Theophylline—Diarrhoea—Etoposide—testicular cancer	0.000312	0.000984	CcSEcCtD
Theophylline—Flushing—Doxorubicin—testicular cancer	0.000309	0.000974	CcSEcCtD
Theophylline—Tension—Epirubicin—testicular cancer	0.000308	0.000969	CcSEcCtD
Theophylline—PDE3B—Signaling Pathways—INSL3—testicular cancer	0.000307	0.00287	CbGpPWpGaD
Theophylline—HDAC2—Signaling by NGF—KITLG—testicular cancer	0.000307	0.00287	CbGpPWpGaD
Theophylline—Nervousness—Epirubicin—testicular cancer	0.000304	0.000959	CcSEcCtD
Theophylline—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	0.000302	0.00282	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—INSL3—testicular cancer	0.000302	0.00282	CbGpPWpGaD
Theophylline—Dizziness—Etoposide—testicular cancer	0.000302	0.000951	CcSEcCtD
Theophylline—Arrhythmia—Doxorubicin—testicular cancer	0.000298	0.000938	CcSEcCtD
Theophylline—Nausea—Cisplatin—testicular cancer	0.000296	0.000932	CcSEcCtD
Theophylline—Alopecia—Doxorubicin—testicular cancer	0.000294	0.000928	CcSEcCtD
Theophylline—CYP2E1—Biological oxidations—HPGDS—testicular cancer	0.000294	0.00275	CbGpPWpGaD
Theophylline—Convulsion—Methotrexate—testicular cancer	0.00029	0.000914	CcSEcCtD
Theophylline—Vomiting—Etoposide—testicular cancer	0.00029	0.000914	CcSEcCtD
Theophylline—Agitation—Epirubicin—testicular cancer	0.000288	0.000908	CcSEcCtD
Theophylline—Rash—Etoposide—testicular cancer	0.000288	0.000907	CcSEcCtD
Theophylline—PDE4A—Signaling Pathways—INSL3—testicular cancer	0.000288	0.00269	CbGpPWpGaD
Theophylline—Dermatitis—Etoposide—testicular cancer	0.000287	0.000906	CcSEcCtD
Theophylline—Headache—Etoposide—testicular cancer	0.000286	0.000901	CcSEcCtD
Theophylline—ADORA2A—Signaling by NGF—KITLG—testicular cancer	0.000285	0.00266	CbGpPWpGaD
Theophylline—Tension—Doxorubicin—testicular cancer	0.000285	0.000897	CcSEcCtD
Theophylline—Nervousness—Doxorubicin—testicular cancer	0.000282	0.000887	CcSEcCtD
Theophylline—PDE3A—Signaling Pathways—INSL3—testicular cancer	0.00028	0.00261	CbGpPWpGaD
Theophylline—CYP1A1—Biological oxidations—HPGDS—testicular cancer	0.000277	0.00259	CbGpPWpGaD
Theophylline—Palpitations—Epirubicin—testicular cancer	0.000277	0.000873	CcSEcCtD
Theophylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000276	0.00257	CbGpPWpGaD
Theophylline—Anaphylactic shock—Methotrexate—testicular cancer	0.000273	0.000861	CcSEcCtD
Theophylline—Convulsion—Epirubicin—testicular cancer	0.000272	0.000856	CcSEcCtD
Theophylline—Infection—Methotrexate—testicular cancer	0.000272	0.000856	CcSEcCtD
Theophylline—Nausea—Etoposide—testicular cancer	0.000271	0.000854	CcSEcCtD
Theophylline—ADORA1—Signaling Pathways—INSL3—testicular cancer	0.000269	0.00252	CbGpPWpGaD
Theophylline—Nervous system disorder—Methotrexate—testicular cancer	0.000268	0.000845	CcSEcCtD
Theophylline—Agitation—Doxorubicin—testicular cancer	0.000267	0.00084	CcSEcCtD
Theophylline—PDE4B—Signaling Pathways—INSL3—testicular cancer	0.000266	0.00249	CbGpPWpGaD
Theophylline—Anxiety—Epirubicin—testicular cancer	0.000266	0.000838	CcSEcCtD
Theophylline—Anorexia—Methotrexate—testicular cancer	0.000261	0.000821	CcSEcCtD
Theophylline—Palpitations—Doxorubicin—testicular cancer	0.000256	0.000808	CcSEcCtD
Theophylline—Anaphylactic shock—Epirubicin—testicular cancer	0.000256	0.000806	CcSEcCtD
Theophylline—Hypotension—Methotrexate—testicular cancer	0.000255	0.000805	CcSEcCtD
Theophylline—CYP2C8—Biological oxidations—HPGDS—testicular cancer	0.000254	0.00238	CbGpPWpGaD
Theophylline—Infection—Epirubicin—testicular cancer	0.000254	0.000801	CcSEcCtD
Theophylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000253	0.00236	CbGpPWpGaD
Theophylline—Shock—Epirubicin—testicular cancer	0.000252	0.000793	CcSEcCtD
Theophylline—Convulsion—Doxorubicin—testicular cancer	0.000251	0.000792	CcSEcCtD
Theophylline—Nervous system disorder—Epirubicin—testicular cancer	0.000251	0.00079	CcSEcCtD
Theophylline—Tachycardia—Epirubicin—testicular cancer	0.00025	0.000787	CcSEcCtD
Theophylline—Insomnia—Methotrexate—testicular cancer	0.000247	0.000779	CcSEcCtD
Theophylline—Anxiety—Doxorubicin—testicular cancer	0.000246	0.000775	CcSEcCtD
Theophylline—Anorexia—Epirubicin—testicular cancer	0.000244	0.000768	CcSEcCtD
Theophylline—Hypotension—Epirubicin—testicular cancer	0.000239	0.000753	CcSEcCtD
Theophylline—Decreased appetite—Methotrexate—testicular cancer	0.000238	0.000749	CcSEcCtD
Theophylline—Anaphylactic shock—Doxorubicin—testicular cancer	0.000237	0.000746	CcSEcCtD
Theophylline—Infection—Doxorubicin—testicular cancer	0.000235	0.000741	CcSEcCtD
Theophylline—Shock—Doxorubicin—testicular cancer	0.000233	0.000734	CcSEcCtD
Theophylline—Nervous system disorder—Doxorubicin—testicular cancer	0.000232	0.000731	CcSEcCtD
Theophylline—Insomnia—Epirubicin—testicular cancer	0.000231	0.000729	CcSEcCtD
Theophylline—Tachycardia—Doxorubicin—testicular cancer	0.000231	0.000728	CcSEcCtD
Theophylline—HDAC2—Signaling by NGF—FGFR3—testicular cancer	0.000228	0.00213	CbGpPWpGaD
Theophylline—Anorexia—Doxorubicin—testicular cancer	0.000226	0.000711	CcSEcCtD
Theophylline—HDAC2—Signaling Pathways—INSL3—testicular cancer	0.000224	0.00209	CbGpPWpGaD
Theophylline—Gastrointestinal pain—Methotrexate—testicular cancer	0.000224	0.000704	CcSEcCtD
Theophylline—Decreased appetite—Epirubicin—testicular cancer	0.000222	0.000701	CcSEcCtD
Theophylline—Hypotension—Doxorubicin—testicular cancer	0.000221	0.000697	CcSEcCtD
Theophylline—Urticaria—Methotrexate—testicular cancer	0.000217	0.000684	CcSEcCtD
Theophylline—Abdominal pain—Methotrexate—testicular cancer	0.000216	0.000681	CcSEcCtD
Theophylline—Body temperature increased—Methotrexate—testicular cancer	0.000216	0.000681	CcSEcCtD
Theophylline—Insomnia—Doxorubicin—testicular cancer	0.000214	0.000675	CcSEcCtD
Theophylline—ADORA2A—Signaling by NGF—FGFR3—testicular cancer	0.000212	0.00198	CbGpPWpGaD
Theophylline—HDAC2—Signaling by NGF—KIT—testicular cancer	0.000209	0.00196	CbGpPWpGaD
Theophylline—Gastrointestinal pain—Epirubicin—testicular cancer	0.000209	0.000659	CcSEcCtD
Theophylline—CYP2D6—Biological oxidations—HPGDS—testicular cancer	0.000209	0.00195	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—INSL3—testicular cancer	0.000208	0.00194	CbGpPWpGaD
Theophylline—CYP2C9—Biological oxidations—HPGDS—testicular cancer	0.000207	0.00193	CbGpPWpGaD
Theophylline—Decreased appetite—Doxorubicin—testicular cancer	0.000206	0.000648	CcSEcCtD
Theophylline—Urticaria—Epirubicin—testicular cancer	0.000203	0.00064	CcSEcCtD
Theophylline—Body temperature increased—Epirubicin—testicular cancer	0.000202	0.000637	CcSEcCtD
Theophylline—Abdominal pain—Epirubicin—testicular cancer	0.000202	0.000637	CcSEcCtD
Theophylline—Hypersensitivity—Methotrexate—testicular cancer	0.000201	0.000635	CcSEcCtD
Theophylline—ADORA2A—Signaling by NGF—KIT—testicular cancer	0.000195	0.00182	CbGpPWpGaD
Theophylline—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000194	0.00061	CcSEcCtD
Theophylline—Pruritus—Methotrexate—testicular cancer	0.000193	0.000609	CcSEcCtD
Theophylline—ADA—Metabolism—HPGDS—testicular cancer	0.00019	0.00177	CbGpPWpGaD
Theophylline—Hypersensitivity—Epirubicin—testicular cancer	0.000188	0.000594	CcSEcCtD
Theophylline—Urticaria—Doxorubicin—testicular cancer	0.000188	0.000592	CcSEcCtD
Theophylline—Body temperature increased—Doxorubicin—testicular cancer	0.000187	0.00059	CcSEcCtD
Theophylline—Abdominal pain—Doxorubicin—testicular cancer	0.000187	0.00059	CcSEcCtD
Theophylline—Diarrhoea—Methotrexate—testicular cancer	0.000187	0.000589	CcSEcCtD
Theophylline—Pruritus—Epirubicin—testicular cancer	0.000181	0.00057	CcSEcCtD
Theophylline—Dizziness—Methotrexate—testicular cancer	0.000181	0.00057	CcSEcCtD
Theophylline—CYP1A2—Biological oxidations—HPGDS—testicular cancer	0.000177	0.00165	CbGpPWpGaD
Theophylline—Diarrhoea—Epirubicin—testicular cancer	0.000175	0.000551	CcSEcCtD
Theophylline—Hypersensitivity—Doxorubicin—testicular cancer	0.000174	0.000549	CcSEcCtD
Theophylline—Vomiting—Methotrexate—testicular cancer	0.000174	0.000548	CcSEcCtD
Theophylline—CYP1B1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000173	0.00162	CbGpPWpGaD
Theophylline—Rash—Methotrexate—testicular cancer	0.000172	0.000543	CcSEcCtD
Theophylline—Dermatitis—Methotrexate—testicular cancer	0.000172	0.000543	CcSEcCtD
Theophylline—Headache—Methotrexate—testicular cancer	0.000171	0.00054	CcSEcCtD
Theophylline—Dizziness—Epirubicin—testicular cancer	0.000169	0.000533	CcSEcCtD
Theophylline—Pruritus—Doxorubicin—testicular cancer	0.000167	0.000528	CcSEcCtD
Theophylline—Vomiting—Epirubicin—testicular cancer	0.000163	0.000512	CcSEcCtD
Theophylline—Nausea—Methotrexate—testicular cancer	0.000162	0.000512	CcSEcCtD
Theophylline—Diarrhoea—Doxorubicin—testicular cancer	0.000162	0.00051	CcSEcCtD
Theophylline—Rash—Epirubicin—testicular cancer	0.000161	0.000508	CcSEcCtD
Theophylline—Dermatitis—Epirubicin—testicular cancer	0.000161	0.000508	CcSEcCtD
Theophylline—Headache—Epirubicin—testicular cancer	0.00016	0.000505	CcSEcCtD
Theophylline—Dizziness—Doxorubicin—testicular cancer	0.000157	0.000493	CcSEcCtD
Theophylline—Nausea—Epirubicin—testicular cancer	0.000152	0.000479	CcSEcCtD
Theophylline—Vomiting—Doxorubicin—testicular cancer	0.00015	0.000474	CcSEcCtD
Theophylline—Rash—Doxorubicin—testicular cancer	0.000149	0.00047	CcSEcCtD
Theophylline—Dermatitis—Doxorubicin—testicular cancer	0.000149	0.00047	CcSEcCtD
Theophylline—Headache—Doxorubicin—testicular cancer	0.000148	0.000467	CcSEcCtD
Theophylline—Nausea—Doxorubicin—testicular cancer	0.000141	0.000443	CcSEcCtD
Theophylline—ADA—Metabolism—STK11—testicular cancer	0.000138	0.00129	CbGpPWpGaD
Theophylline—CYP3A4—Biological oxidations—HPGDS—testicular cancer	0.000136	0.00127	CbGpPWpGaD
Theophylline—PDE4C—Signaling Pathways—H2AFZ—testicular cancer	0.000111	0.00104	CbGpPWpGaD
Theophylline—PDE4C—Signaling Pathways—STK11—testicular cancer	0.00011	0.00103	CbGpPWpGaD
Theophylline—HDAC2—Gene Expression—H2AFZ—testicular cancer	0.00011	0.00103	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000106	0.000995	CbGpPWpGaD
Theophylline—HDAC2—Disease—H2AFZ—testicular cancer	0.000102	0.000955	CbGpPWpGaD
Theophylline—PDE4C—Signaling Pathways—KITLG—testicular cancer	0.000102	0.000955	CbGpPWpGaD
Theophylline—ADORA2B—Signaling Pathways—H2AFZ—testicular cancer	0.000101	0.000947	CbGpPWpGaD
Theophylline—ADORA2B—Signaling Pathways—STK11—testicular cancer	0.000101	0.000942	CbGpPWpGaD
Theophylline—PDE3B—Signaling Pathways—H2AFZ—testicular cancer	9.83e-05	0.000919	CbGpPWpGaD
Theophylline—PDE3B—Signaling Pathways—STK11—testicular cancer	9.78e-05	0.000914	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	9.76e-05	0.000912	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—H2AFZ—testicular cancer	9.67e-05	0.000904	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—STK11—testicular cancer	9.62e-05	0.000899	CbGpPWpGaD
Theophylline—HDAC2—Disease—KITLG—testicular cancer	9.41e-05	0.000879	CbGpPWpGaD
Theophylline—ADORA2B—Signaling Pathways—KITLG—testicular cancer	9.33e-05	0.000872	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—H2AFZ—testicular cancer	9.21e-05	0.00086	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—STK11—testicular cancer	9.16e-05	0.000855	CbGpPWpGaD
Theophylline—PDE3B—Signaling Pathways—KITLG—testicular cancer	9.05e-05	0.000845	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—H2AFZ—testicular cancer	8.96e-05	0.000837	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—STK11—testicular cancer	8.91e-05	0.000832	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—KITLG—testicular cancer	8.9e-05	0.000831	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—H2AFZ—testicular cancer	8.62e-05	0.000806	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—STK11—testicular cancer	8.57e-05	0.000801	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—H2AFZ—testicular cancer	8.52e-05	0.000796	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—STK11—testicular cancer	8.47e-05	0.000791	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—KITLG—testicular cancer	8.47e-05	0.000791	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—KITLG—testicular cancer	8.24e-05	0.00077	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	7.95e-05	0.000742	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—KITLG—testicular cancer	7.93e-05	0.000741	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—KITLG—testicular cancer	7.84e-05	0.000732	CbGpPWpGaD
Theophylline—CYP1B1—Metabolism—HPGDS—testicular cancer	7.7e-05	0.000719	CbGpPWpGaD
Theophylline—PDE4C—Signaling Pathways—FGFR3—testicular cancer	7.6e-05	0.00071	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—H2AFZ—testicular cancer	7.16e-05	0.000669	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—STK11—testicular cancer	7.12e-05	0.000665	CbGpPWpGaD
Theophylline—HDAC2—Disease—FGFR3—testicular cancer	6.99e-05	0.000653	CbGpPWpGaD
Theophylline—PDE4C—Signaling Pathways—KIT—testicular cancer	6.98e-05	0.000652	CbGpPWpGaD
Theophylline—ADORA2B—Signaling Pathways—FGFR3—testicular cancer	6.93e-05	0.000648	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	6.79e-05	0.000634	CbGpPWpGaD
Theophylline—PDE3B—Signaling Pathways—FGFR3—testicular cancer	6.72e-05	0.000628	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—H2AFZ—testicular cancer	6.66e-05	0.000622	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—STK11—testicular cancer	6.62e-05	0.000618	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—FGFR3—testicular cancer	6.61e-05	0.000618	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—KITLG—testicular cancer	6.59e-05	0.000615	CbGpPWpGaD
Theophylline—HDAC2—Disease—KIT—testicular cancer	6.42e-05	0.0006	CbGpPWpGaD
Theophylline—ADORA2B—Signaling Pathways—KIT—testicular cancer	6.37e-05	0.000595	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—FGFR3—testicular cancer	6.3e-05	0.000588	CbGpPWpGaD
Theophylline—PDE3B—Signaling Pathways—KIT—testicular cancer	6.17e-05	0.000577	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—FGFR3—testicular cancer	6.12e-05	0.000572	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—KITLG—testicular cancer	6.12e-05	0.000572	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—KIT—testicular cancer	6.07e-05	0.000567	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—FGFR3—testicular cancer	5.9e-05	0.000551	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—FGFR3—testicular cancer	5.83e-05	0.000544	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—KIT—testicular cancer	5.78e-05	0.00054	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—KIT—testicular cancer	5.62e-05	0.000525	CbGpPWpGaD
Theophylline—CYP1B1—Metabolism—STK11—testicular cancer	5.6e-05	0.000523	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—KIT—testicular cancer	5.41e-05	0.000506	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—KIT—testicular cancer	5.35e-05	0.0005	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—HPGDS—testicular cancer	5.03e-05	0.00047	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—FGFR3—testicular cancer	4.9e-05	0.000457	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—HPGDS—testicular cancer	4.74e-05	0.000443	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—FGFR3—testicular cancer	4.55e-05	0.000425	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—KIT—testicular cancer	4.5e-05	0.00042	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—HPGDS—testicular cancer	4.35e-05	0.000406	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—KIT—testicular cancer	4.18e-05	0.00039	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—STK11—testicular cancer	3.65e-05	0.000341	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—HPGDS—testicular cancer	3.57e-05	0.000333	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—HPGDS—testicular cancer	3.54e-05	0.000331	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—STK11—testicular cancer	3.45e-05	0.000322	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—STK11—testicular cancer	3.16e-05	0.000295	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—HPGDS—testicular cancer	3.02e-05	0.000282	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—STK11—testicular cancer	2.59e-05	0.000242	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—STK11—testicular cancer	2.57e-05	0.00024	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—HPGDS—testicular cancer	2.33e-05	0.000218	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—STK11—testicular cancer	2.2e-05	0.000205	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—STK11—testicular cancer	1.7e-05	0.000158	CbGpPWpGaD
